Page 82 - GPD-3-4

Gene & Protein in Disease Interleukins-1β, interleukin-8, and the SARS-CoV-2

2020;395(10224):565-574. doi: 10.1016/j.clim.2020.108393
doi: 10.1016/S0140-6736(20)30251-8 12. Huang C, Wang Y, Li X, et al. Clinical features of patients
2. Sohrabi C, Alsafi Z, O’Neill N, et al. Corrigendum to “World infected with 2019 novel coronavirus in Wuhan, China.
Health Organization declares global emergency: A review Lancet. 2020;395(10223):497-506.
of the 2019 novel coronavirus (COVID-19)”. Int J Surg. doi: 10.1016/S0140-6736(20)30183-5
2020;77:217.
13. de Oliveira CM, Sakata RK, Issy AM, Gerola LR, Salomão R.
doi: 10.1016/j.ijsu.2020.02.034 Cytokines and pain. Rev Bras Anestesiol. 2011; 61: 2: 255-
3. De Souza WV, Martelli CMT, Silva AP, et al. The first 265.
hundred days of COVID-19 in Pernambuco State, Brazil: 14. Kraychete D, Calasans M, Valente C. Pro-inflammatory
Epidemiology in historical context. Cad Saude Publica. cytokines and pain. Rev Bras Reumatol. 2006;3(43):199-206.
2020;36(11):e00228220.
doi: 10.1590/S0482-50042006000300007
doi: 10.1590/0102-311X00228220
15. Varella P, Forte W. Citokines: A review. Rev Bras Alergia
4. Aquino EML, Silveira IH, Pescarini JM, et al. Social Imunopatol. 2001;4:146-155.
distancing measures to control the COVID-19 pandemic:
Potential impacts and challenges in Brazil. Cien Saude Colet. 16. Zhang JM, An J. Cytokines, inflammation, and pain. Int
2020;25:2423-2446. Anesthesiol Clin. 2007;45(2):27-37.
doi: 10.1590/1413-81232020256.1.10502020 doi: 10.1097/AIA.0b013e318034194e
5. Governo de Santa Catarina, Secretaria de Estado da Saúde, 17. Raghuwanshi SK, Su Y, Singh V, Haynes K, Richmond A,
Sistema Único de Saúde, Superintendência de Vigilância Richardson RM. The chemokine receptors CXCR1 and
em Saúde, Diretoria de Vigilância Epidemiológica de Santa CXCR2 couple to distinct G protein-coupled receptor
Catarina. Manual De Orientações Da Covid-19 (Vírus kinases to mediate and regulate leukocyte functions.
SARS-CoV-2). Florianópolis: 2020. J Immunol. 2012;189(6):2824-2832.
6. Siddiqi HK, Mehra MR. COVID-19 illness in native and doi: 10.4049/jimmunol.1201114
immunosuppressed states: A clinical-therapeutic staging 18. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF.
proposal. J Heart Lung Transplant. 2020;39(5):405-407.
Progress of the COVID-19 vaccine effort: Viruses, vaccines
doi: 10.1016/j.healun.2020.03.012 and variants versus efficacy, effectiveness and escape. Nat
7. Bakhiet M, Taurin S. SARS-CoV-2: Targeted managements Rev Immunol. 2021;21(10):626-636.
and vaccine development. Cytokine Growth Factor Rev. doi: 10.1038/s41577-021-00592-1
2021;58:16-29.
19. Santos-Pinto CDB, Miranda ES, Osorio-de-Castro CGS.
doi: 10.1016/j.cytogfr.2020.11.001 “Kit-covid” and the Popular Pharmacy Program in Brazil.
8. Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Cad Sáude Pública. 2021;2:1-5.
transmission and pathogenesis. Trends Immunol. 20. Livak KJ, Schmittgen TD. Analysis of relative gene
2020;41(12):1100-1115. expression data using real-time quantitative PCR and the
doi: 10.1016/j.it.2020.10.004 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
9. Kirtipal N, Bharadwaj S, Kang SG. From SARS to doi: 10.1006/meth.2001.1262
SARS-CoV-2, insights on structure, pathogenicity and 21. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory
immunity aspects of pandemic human coronaviruses. Infect cytokines and chemokines in severe acute respiratory
Genet Evol. 2020;85:104502. syndrome. Clin Exp Immunol. 2004;136(1):95-103.
doi: 10.1016/j.meegid.2020.104502 doi: 10.1111/j.1365-2249.2004.02415.x
10. Wu C, Chen X, Cai Y, et al. Risk factors associated with 22. Pascarella G, Strumia A, Piliego C, et al. COVID-19
acute respiratory distress syndrome and death in patients diagnosis and management: A comprehensive review.
with coronavirus disease 2019 pneumonia in Wuhan, China. J Intern Med. 2020;288(2):192-206.
JAMA Intern Med. 2020;180(7):934-943.
doi: 10.1111/joim.13091
doi: 10.1001/jamainternmed.2020.0994
23. Chen N, Zhou M, Dong X, et al. Epidemiological and
11. Zhang W, Zhao Y, Zhang F, et al. The use of anti- clinical characteristics of 99 cases of 2019 novel coronavirus
inflammatory drugs in the treatment of people with severe
coronavirus disease 2019 (COVID-19): The perspectives pneumonia in Wuhan, China: A descriptive study. Lancet.
of clinical immunologists from China. Clin Immunol. 2020;395(10223):507-513.
2020;214:108393. doi: 10.1016/S0140-6736(20)30211-7

Volume 3 Issue 4 (2024) 8 doi: 10.36922/gpd.4076